Sagimet Biosciences (SGMT) announced it will host a virtual key opinion leader, KOL, event on Thursday, May 29, 2025. The event will feature Rohit Loomba, MD, MHSc, who will join company management to discuss the potential for developing a combination of denifanstat, a fat synthesis inhibitor, with a fat oxidizer, such as resmetirom, a thyroid hormone beta receptor agonist, to treat advanced metabolic dysfunction-associated steatohepatitis. The planned development program builds upon the successful results of the Phase 2b FASCINATE-2 clinical trial of denifanstat in MASH F2-F3 patients, particularly in more advanced F3 stage patients, as well as on preclinical data demonstrating the synergistic effect of a FASN inhibitor combined with resmetirom on important liver disease markers.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives
- Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer
- Sagimet Biosciences Reports Q1 2025 Financial Results
- Sagimet Biosciences Reports Q1 Financial Results and Updates
- Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue